Somatrogon (Ngenla®) – Growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years of age


Start date 01.04.2022
Resolution 15.09.2022
INN Somatrogon
Brand name Ngenla®
Pharm. company Pfizer Pharma GmbH
G-BA procedure ID 2022-04-01-D-800
Therapeutic area Metabolic diseases ORPHAN
Reason for procedure Initial assessment

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Ngenla is used for the treatment of children and adolescents from the age of 3 years with growth disorders caused by insufficient secretion of growth hormone.

Subpopulation Indication Comparator
Kinder und Jugendliche ab 3 Jahren mit Wachstumsstörung durch unzureichende Ausschüttung von Wachstumshormon Not applicable

9. Associated procedures

<< List of all resolutions